title: Notching up a new therapeutic strategy for non-small cell lung carcinoma (NSCLC).
abstract: Our results open a new therapeutic opportunity to treat NSCLC using GSIs. Interestingly, GSIs have been used in long-term treatments in Alzheimer´s patients without major side effects (although without improving the course of the disease). The accumulated knowledge on the pharmacology of GSIs should pave the way to test these compounds in NSCLC patients.
authors.forename: Antonio
authors.initials: A
authors.lastname: Maraver
authors.forename: Manuel
authors.initials: M
authors.lastname: Serrano
mesh_terms: D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051379:Mice; D011480:Protease Inhibitors / Q000494:pharmacology*; D051880:Receptors, Notch / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D011480:Protease Inhibitors; D051880:Receptors, Notch; D053829:Amyloid Precursor Protein Secretases